MX2020004659A - Regimen de dosificacion de edasalonexent para el tratamiento de distrofia muscular. - Google Patents
Regimen de dosificacion de edasalonexent para el tratamiento de distrofia muscular.Info
- Publication number
- MX2020004659A MX2020004659A MX2020004659A MX2020004659A MX2020004659A MX 2020004659 A MX2020004659 A MX 2020004659A MX 2020004659 A MX2020004659 A MX 2020004659A MX 2020004659 A MX2020004659 A MX 2020004659A MX 2020004659 A MX2020004659 A MX 2020004659A
- Authority
- MX
- Mexico
- Prior art keywords
- muscular dystrophy
- edasalonexent
- dosing regimen
- treating muscular
- subject
- Prior art date
Links
- 229950002185 edasalonexent Drugs 0.000 title abstract 2
- 201000006938 muscular dystrophy Diseases 0.000 title abstract 2
- JQLBBYLGWHUHRW-KUBAVDMBSA-N n-[2-[[(4z,7z,10z,13z,16z,19z)-docosa-4,7,10,13,16,19-hexaenoyl]amino]ethyl]-2-hydroxybenzamide Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(=O)NCCNC(=O)C1=CC=CC=C1O JQLBBYLGWHUHRW-KUBAVDMBSA-N 0.000 title abstract 2
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 abstract 2
- 235000014113 dietary fatty acids Nutrition 0.000 abstract 2
- 229930195729 fatty acid Natural products 0.000 abstract 2
- 239000000194 fatty acid Substances 0.000 abstract 2
- 150000004665 fatty acids Chemical class 0.000 abstract 2
- 230000036470 plasma concentration Effects 0.000 abstract 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 abstract 2
- 229960001860 salicylate Drugs 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
La invención proporciona métodos y composiciones para el tratamiento de una distrofia muscular, por ejemplo, distrofia muscular de Duchenne (DMD), en un sujeto, con un salicilato acetilado de ácido graso, por ejemplo, edasalonexent, efectivo para alcanzar un umbral de concentración plasmática del salicilato acetilado de ácido graso en el sujeto, por ejemplo, un umbral de concentración plasmática de al menos alrededor de 20 ng/ml durante al menos 12 horas en un periodo de 24 horas.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762581981P | 2017-11-06 | 2017-11-06 | |
| PCT/US2018/059283 WO2019090271A1 (en) | 2017-11-06 | 2018-11-05 | Edasalonexent dosing regimen for treating muscular dystrophy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020004659A true MX2020004659A (es) | 2020-10-14 |
Family
ID=66332350
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020004659A MX2020004659A (es) | 2017-11-06 | 2018-11-05 | Regimen de dosificacion de edasalonexent para el tratamiento de distrofia muscular. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20210023029A1 (es) |
| EP (1) | EP3706730A4 (es) |
| JP (1) | JP2021502328A (es) |
| KR (1) | KR20200084877A (es) |
| CN (1) | CN111315372A (es) |
| AU (1) | AU2018359969A1 (es) |
| BR (1) | BR112020009020A2 (es) |
| CA (1) | CA3078727A1 (es) |
| CL (1) | CL2020001180A1 (es) |
| CO (1) | CO2020006395A2 (es) |
| IL (1) | IL274375A (es) |
| MX (1) | MX2020004659A (es) |
| PH (1) | PH12020550526A1 (es) |
| RU (1) | RU2020118258A (es) |
| SG (1) | SG11202004115WA (es) |
| WO (1) | WO2019090271A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020191087A1 (en) * | 2019-03-18 | 2020-09-24 | Ptc Therapeutics, Inc. | Therapeutic combinations for use in treating a muscular dystrophy |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2315740B1 (en) * | 2008-07-08 | 2017-10-25 | Catabasis Pharmaceuticals, Inc. | Fatty acid acetylated salicylates and their uses |
| PL2519230T3 (pl) * | 2009-12-31 | 2019-05-31 | Marius Pharmaceuticals Llc | Modulacja rozpuszczalności, stabilności, absorpcji, metabolizmu i profilu farmakokinetycznego leków lipofilowych przez sterole |
| JP5771627B2 (ja) * | 2010-01-08 | 2015-09-02 | カタバシス ファーマシューティカルズ，インコーポレイテッド | 脂肪酸フマル酸塩誘導体およびそれらの使用 |
-
2018
- 2018-11-05 KR KR1020207015893A patent/KR20200084877A/ko not_active Withdrawn
- 2018-11-05 WO PCT/US2018/059283 patent/WO2019090271A1/en not_active Ceased
- 2018-11-05 US US16/761,783 patent/US20210023029A1/en not_active Abandoned
- 2018-11-05 CA CA3078727A patent/CA3078727A1/en not_active Abandoned
- 2018-11-05 JP JP2020520142A patent/JP2021502328A/ja active Pending
- 2018-11-05 CN CN201880071203.6A patent/CN111315372A/zh active Pending
- 2018-11-05 RU RU2020118258A patent/RU2020118258A/ru unknown
- 2018-11-05 AU AU2018359969A patent/AU2018359969A1/en not_active Abandoned
- 2018-11-05 BR BR112020009020-4A patent/BR112020009020A2/pt not_active Application Discontinuation
- 2018-11-05 EP EP18874489.0A patent/EP3706730A4/en not_active Withdrawn
- 2018-11-05 MX MX2020004659A patent/MX2020004659A/es unknown
- 2018-11-05 SG SG11202004115WA patent/SG11202004115WA/en unknown
-
2020
- 2020-04-30 PH PH12020550526A patent/PH12020550526A1/en unknown
- 2020-04-30 IL IL274375A patent/IL274375A/en unknown
- 2020-05-05 CL CL2020001180A patent/CL2020001180A1/es unknown
- 2020-05-27 CO CONC2020/0006395A patent/CO2020006395A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3706730A4 (en) | 2021-08-11 |
| PH12020550526A1 (en) | 2021-05-10 |
| CO2020006395A2 (es) | 2020-06-09 |
| CN111315372A (zh) | 2020-06-19 |
| US20210023029A1 (en) | 2021-01-28 |
| CA3078727A1 (en) | 2019-05-09 |
| KR20200084877A (ko) | 2020-07-13 |
| BR112020009020A2 (pt) | 2020-10-27 |
| CL2020001180A1 (es) | 2020-09-25 |
| IL274375A (en) | 2020-06-30 |
| SG11202004115WA (en) | 2020-06-29 |
| JP2021502328A (ja) | 2021-01-28 |
| AU2018359969A1 (en) | 2020-05-14 |
| RU2020118258A (ru) | 2021-12-08 |
| EP3706730A1 (en) | 2020-09-16 |
| WO2019090271A1 (en) | 2019-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1125136T1 (el) | Συνθεσεις που περιλαμβανουν βακτηριακα στελεχη | |
| CY1124013T1 (el) | Συνθεσεις που περιλαμβανουν βακτηριακα στελεχη | |
| CY1122148T1 (el) | Συνθεσεις που περιεχουν βακτηριακα στελεχη | |
| AR101312A1 (es) | Combinaciones de inhibidores de bet e inhibidores de tirosina quinasa de bruton | |
| CO2020004034A2 (es) | Métodos para el tratamiento de distrofia muscular | |
| EA201891199A1 (ru) | Композиции, содержащие бактериальные штаммы | |
| CL2016003422A1 (es) | Inhibidores de demetilasa-1 específico de lisina | |
| EA201890811A1 (ru) | Способы лечения мышечной дистрофии | |
| CL2017002031A1 (es) | Formulación en polvo nasal para el tratamiento de hipoglicemia | |
| MX2019007187A (es) | Composiciones para el cuidado bucal. | |
| CL2016003423A1 (es) | Inhibidores de demetilasa-1 específico de lisina | |
| EA201790787A1 (ru) | Снижение вязкости фармацевтических составов | |
| EA201791467A1 (ru) | Водный офтальмологический раствор | |
| EA201490688A1 (ru) | 2-тиопиримидиноны | |
| MX2016011938A (es) | Composicion farmaceutica liquida. | |
| MX381776B (es) | Formulacion acuosa que comprende paracetamol e ibuprofeno. | |
| CL2016002879A1 (es) | Composiciones farmacéuticas para tratar enfermedades infecciosas | |
| MX2022013283A (es) | Composiciones para limpieza de colon y tratamiento de trastornos gastrointestinales. | |
| JOP20200126B1 (ar) | طرق استخدام وتركيبات تحتوي على دولاجلوتيد | |
| MX386107B (es) | Composiciones para el cuidado bucal. | |
| CL2017000118A1 (es) | Métodos y composiciones para tratar desórdenes relacionados con el vih | |
| CO2020006395A2 (es) | Régimen de dosificación de edasalonexent para el tratamiento de distrofia muscular | |
| MX2017009313A (es) | Formulaciones intravenosas de baclofeno y metodos de tratamiento. | |
| CO2019007531A2 (es) | 3-hidroxibutirato solo o en combinación para su uso en el tratamiento de cuidados intensivos | |
| UA91618U (uk) | Антимікробний засіб паммосепт плюс |